| Summary: | Prostate cancer (PCa) is the second most common cancer in Western men; with over 30,000 new cases are diagnosed in the UK each year. Primarily treatment involves targeting the androgen-signalling pathway by blocking production of testicular androgens and/or inhibiting AR function. Current treatments depend on the age and health of the patient. These treatments range from a watch and wait strategy to androgen ablation therapy, by chemical or surgical castration, with the addition of using anti-androgens to block the AR function. The drawbacks of these treatments include loss of bone mineral density, urinary dysfunction, bowel dysfunction, erectile dysfunction, loss off libido and fertility.
|
|---|
